Amwill Health (544353)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 27.56% indicates strong capital efficiency.
• P/E of 8.63 offers potential valuation support if earnings stabilise.
• Latest quarter net margin is roughly 19% (₹4 crore profit on ₹21 crore sales), showing recent profitability.
• Small market cap of ₹70 crore leaves room for a low-base recovery if operations improve.

Concerns

• Sales fell 8.42% and profit fell 40.64%, showing clear business deterioration.
• Piotroski F-Score of 3/9 points to weak financial health and possible operational stress.
• Zero dividend yield means investors receive no income while waiting for a recovery.
• Missing data on book value, debt/equity, promoter holding and 52-week range severely limits proper due diligence.

AI Analysis

Looking at Amwill Health, I see a small pharmaceutical business at ₹34.85 with a market cap of just ₹70 crore. At first glance, the P/E of 8.63 catches my eye, but cheapness alone is never enough. Graham taught me to buy with a margin of safety backed by stable earning power and a sound balance sheet. Here, the figures tell a mixed and somewhat troubling story. ROCE is a healthy 27.56%, suggesting efficient use of capital, but sales declined 8.42% and profits fell 40.64%. That kind of divergence—profits falling four times faster than revenue—makes me question the quality and durability of earnings. Piotroski F-score of 3 out of 9 is a red flag: it points to deteriorating fundamentals, weak operating efficiency, or increasing financial stress. The latest quarter does show a net profit of ₹4 crore on revenue of ₹21 crore, which would imply an attractive net margin, but one quarter cannot offset a trailing decline. I also see no dividend, no promoter holding disclosure, no book value, and no debt-equity data. As an investor, I cannot underwrite what I cannot see. A low P/E in a small pharmaceutical company with negative growth can be a value trap, not an opportunity. I would need evidence of stabilisation—several quarters of consistent cash generation, a better F-score, and clearer governance—before committing capital. In Buffett's words, it is better to pay a fair price for a wonderful business than a cheap price for a troubled one. Right now, Amwill looks like a possible turnaround, not a proven one.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer